Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04623216
- Locations
- 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4978
- Registration Number
- NCT04614831
- Locations
- 🇨🇭
Novartis Investigational Site, Basel, Switzerland
A First-in-Human Study of CEE321 in Adult Subjects
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04612062
- Locations
- 🇯🇵
Novartis Investigative Site, Hachioji, Tokyo, Japan
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT04597632
- Locations
- 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 451
- Registration Number
- NCT04593927
- Locations
- 🇯🇵
Novartis Investigative Site, Tokushima, Japan
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 205
- Registration Number
- NCT04589650
- Locations
- 🇺🇸
UCSF Birthmarks and Vascular Center, San Francisco, California, United States
🇺🇸Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸CHOP Abramson Pediatric Resch Ctr, Philadelphia, Pennsylvania, United States
Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04589663
- Locations
- 🇿🇦
Novartis Investigative Site, Cape Town, South Africa
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04587622
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04582409
- Locations
- 🇩🇪
Novartis Investigative Site, Frankfurt, Germany
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 519
- Registration Number
- NCT04578834
- Locations
- 🇺🇸
AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona, United States
🇺🇸AKDHC Medical Research ServicesLLC, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States